Easywell Biomedicals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was TWD 68.15 million compared to TWD 42.06 million a year ago. Net loss was TWD 27.12 million compared to TWD 25.78 million a year ago. Basic loss per share from continuing operations was TWD 0.24 compared to TWD 0.23 a year ago.
For the nine months, sales was TWD 174.59 million compared to TWD 112.05 million a year ago. Net loss was TWD 100.54 million compared to TWD 115.29 million a year ago. Basic loss per share from continuing operations was TWD 0.88 compared to TWD 1.01 a year ago.